HIF1A and hepatocellular carcinoma: Only preventive HIF-1α ASO administration resulted in significant hepatic enlargement in HCC mice compared to healthy control mice and other treatment groups, whereas in the therapeutic setting, both HIF-1α and HIF-2α ASO treatment resulted in significant hepatomegaly (Figure 4A).